Moleculin Biotech, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $79.0M | $70.9M |
| FY2022 | — | $52.2M | $43.1M |
| FY2023 | — | $30.9M | $23.6M |
| FY2024 | — | $11.2M | $4.3M |
| FY2025 | — | $15.0M | $8.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $79.0M | $70.9M |
| FY2022 | — | $52.2M | $43.1M |
| FY2023 | — | $30.9M | $23.6M |
| FY2024 | — | $11.2M | $4.3M |
| FY2025 | — | $15.0M | $8.9M |